We're driven by opportunity and the transformative nature of technology. Our holdings are multi-sector. Non-chemical disinfectants. Audio therapy for tinnitus. Next generation computer memory. Therapeutic devices. Nano-scale fuel cells.
The common thread among our investments: The ability to transform leading-edge research into commercial success. But it takes more than the promise of innovation to earn a place as an Allied Minds subsidiary. Every one of our investments also has an attractive risk-return profile, a deliverable timeline and potential products that will be groundbreaking in their respective fields.
Developing critical enabling technologies for the next-generation of wireless communications by improving supply, demand, and delivery of spectrum for future cellular communications.
Allied Minds Devices is focused on developing transformative technologies into commercially viable medical device products within two years.
Developing and commercializing best-of-breed technology from U.S. federal research institutions.
Enabling the next generation of implantable electrostimulation and sensing products through the development of proprietary, high-performance, conducting polymers.
Broadcast Routing Fountains is building a novel Internet architecture that efficiently and securely leverages broadcast channels for disseminating routing information.
Cephalogics is developing an noninvasive, bedside brain monitor to improve outcomes in patients with neurological injury while reducing costs and hospital stays.
CryoXtract offers the only solutions to aliquot frozen banked biosamples without exposing them to damaging freeze/thaw cycles.
Foreland Technologies is a cyber security platform company for the discovery, incubation and commercialization of emerging technologies.
Illumasonix is working to easily and non-invasively provide near real-time assessment of detailed blood flow patterns within the cardiovascular system.
LuxCath is developing a catheter based real-time visualization technology for use during cardiac ablation procedures.
Optio Labs develops transformational mobile security technologies for today’s rapidly evolving cyber operating environment.
PAR Works brings augmented reality to a new level, offering imagery overlay accuracy in millimeters, all performed in a matter of seconds.
Precision Biopsy is developing a novel medical device platform utilizing tissue spectroscopy to distinguish tissue characteristics in real-time and to guide clinicians toward optimum therapy and its effectiveness.
ProGDerm is developing a unique biologic that represents the only true, natural approach to generate subcutaneous fat to enhance the appearance of skin using the body’s own processes.
RF Biocidics makes food safe from insects and pathogens through a game changing process that does not use chemicals, is organic, and does not alter sensory or nutritional characteristics.
SaltCheck is the only instantaneous point of care urine spot test that can be deployed at home, to measure dietary salt intake for the 600 million hypertension sufferers worldwide.
SciFluor Life Sciences is harnessing the transformational power of fluorine to enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies.
SiEnergy Systems is developing thin film low temperature SOFC that brings highly efficient, and affordable clean energy systems for broad application.
SoundCure has developed an FDA-Cleared consumer medical device that will be the market leader in tinnitus therapy offering breakthrough, customized acoustic technology to the 10% of the adults that suffers from this often debilitating condition.
Commercializing a breakthrough MRAM computer memory that has demonstrated superior performance over other memories and is poised to become the first universal memory technology in this $70 billion market.